Advertisement
"The TAXUS Liberte Stent is a major advance in stent development andraises the bar for drug-eluting stent systems," said Serge Doucet, M.D.,Cathlab Director at the Montreal Heart Institute. "It offers enhanced abilityto conform to the vessel wall and deliver across some of the most challenginglesions. This innovation is welcome news for interventional cardiologists andpatients in Canada who suffer from coronary artery disease."
Advertisement
"This stent is designed specifically for improved drug elution anddeliverability," said David McFaul, Boston Scientific Senior Vice President,International. "Coupled with our proven paclitaxel-eluting technology, TAXUSLiberte provides physicians with next-generation performance. We aredelighted that Canadian physicians and patients can now benefit from thishighly advanced technology for the treatment of coronary artery disease."
Currently the leading drug-eluting stents worldwide, TAXUS Stent Systemshave been evaluated by the industry's most extensive randomized, controlledclinical trial program, as well as studied in more than 35,000 real-worldpatients enrolled in post-approval registries. To date, approximately fourmillion TAXUS Stents have been implanted worldwide.
The TAXUS Liberte Stent has previously been approved for sale in Europeand other international markets and is currently awaiting approval by the U.S.Food and Drug Administration and is not available for sale in the UnitedStates.
Boston Scientific is a worldwide developer, manufacturer and marketer ofmedical devices whose products are used in a broad range of interventionalmedical specialties. For more information, please visit:www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaningof Section 21E of the Securities Exchange Act of 1934. Forward-lookingstatements may be identified by words like "anticipate," "expect," "project,""believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates usinginformation available to us at the time and are not intended to be guaranteesof future events or performance. These forward-looking statements include,among other things, statements regarding our product performance, regulatoryapproval of our products, new product launches, competitive offerings, ourgrowth strategy, and our market position. If our underlying assumptions turnout to be incorrect, or if certain risks or uncertainties materialize, actualresults could vary materially from the expectations and projections expressedor implied by our forward-looking statements. These factors, in some cases,have affected and in the future (together with other factors) could affect ourability to implement our business strategy and may cause actual results todiffer materially from those contemplated by the statements expressed in thispress release. As a result, readers are cautioned not to place undue relianceon any of our forward-looking statements.
Factors that may cause such differences include, among other things:future economic, competitive, reimbursement and regulatory conditions; newproduct introductions; demographic trends; intellectual property; litigation;financial market conditions; and, future business decisions made by us and ourcompetitors. All of these factors are difficult or impossible to pr
